Vast is a preclinical airway immunology company focused on breaking the vicious cycle of infection and chronic inflammation in respiratory diseases.
The Vast technology platform begins with the unmatched antimicrobial activity of nitric oxide in the form of stable prodrugs. When our new chemical entities are combined with inhalation formulation expertise and proprietary chemistry for delivering drug candidates to the lungs, the result is aerosolized therapies targeting the specific needs of individual patient populations.
Nitric oxide is an endogenous molecule that plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Durham, Nc
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vasttherapeutics.com
- Keywords
- Pharmaceuticals, Biotech, Therapeutics.
- HQ
- Durham, NC
Vast Therapeutics Questions
Vast Therapeutics's website is http://www.vasttherapeutics.com
Vast Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vasttx
Vast Therapeutics has
12 employees.
View email and phone details for 12
employees at Vast Therapeutics.
Vast Therapeutics's industry is
Biotechnology Research
Vast Therapeutics's top competitors are
4m Therapeutics Inc.,
Emitbio Inc.,
Kriya Therapeutics, Inc.,
Merakris Therapeutics, Inc.,
Belhaven Biopharma,
Know Bio, Llc,
Fennec Pharmaceuticals Inc,
Enalare Therapeutics Inc.,
Revian,
Veloxis Pharmaceuticals, Inc..
Vast Therapeutics's categories are Biotechnology Research
Vast Therapeutics's founding year is 2017
